Thiopental
- Atc Codes:N01AF03#N05CA19
- CAS Codes:71-73-8#76-75-5
- PHARMGKB ID:71-73-8#76-75-5
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Thiopental; Belgium: Pentothal; Bulgaria: Thiopental; Czech Republic: Thiopental; Denmark: Pentothal; Estonia: Thiopental; Finland: Pentothal; France: Pentothal; Germany: Thiopental, Thiopentone, Trapanal; Greece: Pentothal, Thiopental; Hungary: Thiopental; Ireland: Thiopental; Italy: Farmotal, Pentothal, Tiopen S; Latvia: Thiopental; Lithuania: Thiopental; Luxembourg: Nesdonal, Pentothal; Malta: Thiopental, Thiopentone; Netherlands: Pentothal; Poland: Thiopental; Portugal: Pentothal, Tiopental; Romania: Thiopental; Slovakia: Thiopental; Spain: Pentothal, Tiobarbital; Sweden: Pentothal; UK: Thiopental.
North America
Canada: Pentothal.
Latin America
Argentina: Bensulf, Hipnopento, Tiopental; Brazil: Thionembutal, Thiopentax; Mexico: Pentarim, Pentothal, Sodipental.
Asia
Japan: Ravonal.
Drug combinations
Chemistry
Thiopental Sodium: C~11~H~17~N~2~NaO~2~S. Mw: 264.32. (1) 4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-(1-methylbutyl)-2-thioxo-, monosodium salt, (±)-; (2) Sodium (±)-5-ethyl-5-(1-methylbutyl)-2-thiobarbiturate. CAS-71-73-8; CAS-76-75-5 (thiopental).
Pharmacologic Category
General Anesthetics; Barbiturates. Barbiturate Anticonvulsant. (ATC-Code: N01AF03; N05CA19).
Mechanism of action
Short-acting barbiturate with sedative, hypnotic, and anticonvulsant properties. Barbiturates depress sensory cortex, decrease motor activity, alter cerebellar function, and produce drowsiness, sedation, and hypnosis. In high doses, barbiturates exhibit anticonvulsant activity.
Therapeutic use
Induction of anesthesia. Adjunct for intubation in head injury patients. Control of convulsive states. Treatment of elevated intracranial pressure.
Pregnancy and lactiation implications
Unlabeled use
Contraindications
Hypersensitivity to thiopental, barbiturates, or any component of the formulation. Status asthmaticus. Severe cardiovascular disease. Porphyria (variegate or acute intermittent). Should not be administered by intra-arterial injection.
Warnings and precautions
May cause hypotension. Use with caution in hemodynamically unstable patients (hypotension or shock). May cause laryngospasm or bronchospasms (use with extreme caution in reactive airway diseases (asthma or COPD)). May cause paradoxical responses, including agitation and hyperactivity, particularly in acute pain and pediatric patients. May cause respiratory depression (use with caution in respiratory disease). Use with caution in Addison’s disease (may prolong or potentiate hypnotic effect). Use with caution in severe anemia (may prolong or potentiate hypnotic effect), in unstable aneurysms, in cardiovascular disease, in hepatic impairment, myasthenia gravis, myxedema, and renal impairment (may prolong or potentiate hypnotic effect), and in history of drug abuse (potential for drug dependency exists). Effects with other sedative drugs or ethanol may be potentiated. Use with caution in debilitated patients, and in excessively premedicated patients (may prolong or potentiate hypnotic effect). Do not administer in acute pain. Repeated dosing or continuous infusions may cause cumulative effects. Extravasation or intra-arterial injection causes necrosis due to pH of 10.6. Anticonvulsants should not be discontinued abruptly due to possibility of increasing seizure frequency.